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Abstract
Background: Osteoporosis results in fractures and treatment of osteoporosis has been shown to reduce
risk of fracture particularly in those who have had a history of fracture.
Methods: A prospective study was conducted using patients admitted to a hip fracture rehabilitation
program at a large referral center to evaluate the use of treatments recommended for secondary
prevention of osteoporotic fracture between September 1, 2001 and September 30, 2003. The frequency
of medication use for the treatment of osteoporosis including estrogen replacement therapy,
bisphosponates, calcitonin, calcium and vitamin D therapy was determined on admission, at 6 weeks post
discharge and one year following discharge. All patients were discharged to the care of their family
physician. All family physicians in the referral region received a copy of the Canadian Consensus
recommendations for osteoporosis management 1–3 months prior to the study.
Results: During the study period, 174 patients were enrolled and 121 completed all assessments. Fifty-
seven family physicians were identified as caring for 1 or more of the study patients. Only 7 patients had
previous BMD, only 5 patients had previously been prescribed a bisphosponate and 14 patients were taking
calcium and/or vitamin D. All patients were prescribed 2500 mg calcium, 400 IU vitamin D and 5 mg
residronate daily during rehabilitation and at discharge.
Following discharge, a significant improvement was seen in all clinical indices of functional mobility,
including the functional independence measure (FIM), walking distance, fear of falling score (FFS), and the
Berg balance score (BBS). At six weeks a significant (p < 0.01) decrease in calcium and vitamin D use was
observed. All patients remained compliant with residronate therapy. At twelve months 71 patients
remained on residronate (p < 0.01), 10 were now taking alternate bisphosphonate therapy and few were
taking calcium and/or vitamin D (p < 0.001). FIM, FFS and Berg scores were significantly decreased from
discharge (p < 0.001) while walking distance was unchanged.
Conclusion: Few patients admitted for hip fracture had previously taken recommended osteoporosis
therapy including bisphosphonates. While compliance with Canadian Consensus recommendations was
observed at six weeks, this was not the case at twelve months post hip fracture rehabilitation.
Interventions to improve not only the detection and treatment of osteoporosis but also the ongoing
treatment and management post-fracture need to be developed and implemented.
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Background
Osteoporosis is a chronic and progressive condition that
leads to decreased bone mass and skeletal fragility; in
turn, these conditions can lead to fractures, disability,
pain and even death. [1-5]
The lifetime risk for a typical osteoporotic fracture (for
example of the wrist, hip or vertebrae) is about 40%. [1-4]
The annual cost of treatment of osteoporosis and its
sequela in the United States is estimated about $13.8 bil-
lion dollars [1,3-5] compared with $7.5 billion dollars for
congestive heart failure and $6.2 billion for asthma[6].
Ideally, osteoporosis should be prevented before bone
mass is lost or fractures occur. Nevertheless, an important
complimentary strategy is to identify patients who already
have had a typical osteoporotic fracture and institute treat-
ments aimed a further secondary prevention. [4-7] In post
menopausal women, at least 80%–90% of fractures of the
wrist, hip or vertebrae are associated with osteoporosis,
[8-10] and a patient with both osteoporosis and a fracture
has approximately a twenty-fold risk of future fracture
compared with a patient who has neither osteoporosis
nor a history of fracture.[2,9,11] Furthermore, the risk of
recurrent fracture begins to rise within the first months
and year of the index fracture event.[12] Because patients
with osteoporosis are at such high risk for recurrent frac-
ture, they may also derive the greatest absolute benefits for
treatment. Since the early 1990's, physicians have had sev-
eral well-tolerated effective therapeutic options that are
described in consensus recommendations including
bisphosphonates, calcitonin and estrogen.[1,2,6,7,13]
These agents have been shown to increase bone mineral
density, and the relative reduction in risk for fracture with
each treatment is about 40 to 60%.[1,2,6,7,13] Moreover,
the benefits of treatment extend to all available subgroups
of patients including the elderly, those with multiple pre-
vious fractures, and those with the lowest bone den-
sity[14].
Despite the relative ease with which high risk patients
with symptomatic fracture can be identified, and given the
availability of effective treatments, some recent studies
have suggested that physicians may be missing important
opportunities for secondary prevention, particularly for
patients with non-vertebral fractures.[4,11,15-20] For
example, the rate of initiation of new osteoporosis treat-
ment has been reported between five and sixteen percent
following a wrist fracture,[4,11,15-17] one to nine percent
following hip fractures,[15,18,19] and eighteen to thirty-
nine percent following symptomatic vertebral frac-
tures.[15,20] Indeed, Andrade et al [20] found that most
women who had experienced a fracture of the hip, verte-
bra or wrist did not receive drug treatment for osteoporo-
sis even up to one year following the fracture. These
previous studies were not population based;[11,16,18-
20] were not restricted to postmenopausal
women;[11,15,16,18,19] did not look at inpatient groups
who were easy to identify and had a short duration of fol-
lowup.[4,18,20] Therefore the existing studies are some-
what limited.
Hence, we undertook the present study in an opportunis-
tic cohort of inpatient hip fracture patients at a muscu-
loskeletal (MSK) rehabilitation referral center to
document the rate of osteoporosis treatment at the time of
fracture and during the year following fracture to examine
correlates of receiving treatment after fracture. We also
supplemented this strategy with a family physician brief
educational intervention to expose them to the Canadian
Consensus recommendations [2] and also obtain infor-
mation regarding their perception of confidence with
treating and preventing osteoporosis in fractures during
this study. We hypothesized that our findings might
expose potential important but missed opportunities for
treatment in the post hip fracture setting or secondary pre-
vention setting.
Methods
We conducted a prospective study among patients admit-
ted for hip fracture rehabilitation in the MSK program at
Parkwood Hospital, London, Ontario (pop ~400,000).
Both men and women who were admitted between three
and seven days post fracture for a three to four week
length of stay rehabilitation program were enrolled
between September 1, 2001 and September 30, 2003.
Informed consent was obtained by the study team and the
study was approved by the University of Western Ontario
Review Board. We excluded patients who had elective
arthroplasty or had multiple trauma beyond the single hip
fracture, had diagnosed cancer or concurrent medical
problems requiring aggressive intervention. The date of
the initial fracture during the study period was identified
while the date of discharge was used as the index for fol-
lowup at six weeks and twelve months.
We reviewed medical histories of the sample on admis-
sion for their ability to fulfill the selection criteria as well
as obtaining a history of current medical problems, con-
comitant medications, BMI, current functional assess-
ment using the functional independence measure (FIM)
[21], the Berg balance score (BBS) [22], fear of falling
score (FFS) [23] and walking distance. We also deter-
mined whether previous osteoporosis treatment was
received including bisphosphonate therapy, calcium and
Vitamin D, and whether a previous BMD had been done.
The inpatient MSK rehabilitation program has been previ-
ously described [24]. In brief, all patients received combi-
nation of occupational and physical therapy at least three
times per week for two one hour periods per session.BMC Family Practice 2006, 7:31 http://www.biomedcentral.com/1471-2296/7/31
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Prior to the study, a brief educational intervention was
delivered by mail to all practicing family physicians
within the referral network of Parkwood Hospital com-
prised of a statement of current Canadian Consensus rec-
ommendations for osteoporosis management [2]. We
determined physician confidence and perception of
knowledge of osteoporosis management using a ten point
visual analog score (VAS) with anchors from 0 (no confi-
dence or no knowledge) to 10 (completely confident or
completely knowledgeable).
All patients were prescribed calcium (1250 mg daily),
vitamin D (400 IU daily) and residronate (5 mg daily)
during rehabilitation and at discharge. Patients were
screened at entry for evidence of Vit D deficiency.
Adverse events were reported and recorded at each meas-
urement period (admission, discharge, 6 weeks and 12
months followup). We also recorded the type of gait
device being used on discharge as well as whether DVT
prophylaxis was prescribed.
The overall frequency of use of osteoporosis therapy dur-
ing the year following the date of discharge from the MSK
rehabilitation program were used to estimate compliance
with current recommendations. A BMD was also done
during the inpatient period and at 12 month followup.
Statistical significance of differences was tested using Pear-
son χ2 statistics and Mantel-Haenszel test for linear asso-
ciation. Logistic regression was used to estimate the
strength of the association between patient characteristics
and the use of treatments for osteoporosis following dis-
charge.
Results
We identified 174 patients (78% female) with a mean age
of 83 ± 10 years (Additional file 1) who were diagnosed
and treated for a fracture of the hip during the study enrol-
ment and followed for one-year post discharge. Fifty-
seven family physicians were identified as primary care
providers for the patient cohort. All physicians had
received the Canadian Consensus recommendations and
completed the two VAS questions prior to the study.
Patients enrolled in the study represented approximately
66% of all admissions to the MSK rehabilitation program
during the study period. Reason for exclusion from the
protocol include refusal to consent, documented intoler-
ance to bisphosponate therapy, multiple trauma, concur-
rent medical illness requiring intensive therapy or cancer.
On admission to the MSK rehabilitation program, 33
women used estrogen therapy, only 14 were using cal-
cium and/or Vitamin D therapy and only 5 had been
using a bisphosphonate medication. None were using cal-
citonin therapy and no men were using calcium, vitamin
D or bisphosphonate. Only 7 patients had a previous
BMD. The BMD score on admission to rehabilitation was
significantly lower among women than men (p < 0.05).
The average FFS was 14 ± 1.3 and all patients reported at
least one previous fall resulting in trauma. Patients were
cognitively intact (having a mini mental status score of 27
± 1.5. Twenty-seven patients had a previous documented
fracture while 6 patients had evidence of vertebral oste-
oporotic fracture. Increasing age was associated with a sig-
nificant (p < 0.05) decrease in previous osteoporosis
treatment or absence of previous BMD. Similarly, increas-
ing age was associated with higher numbers of co-morbid
diagnoses and the number of concomitant medications.
The most common diagnosis was that of hypertension
(39%). Those patients with a previous history of fracture
or osteoporosis treatment had higher scores of fear of fall-
ing and greater number of previous significant falls.
No adverse events were recorded during the rehabilitation
period. One-hundred and six patients were discharged on
DVT prophylaxis with instructions to maintain this
prophylaxis for a total of six weeks post fracture. Mean
length of rehabilitation stay was 3.6 weeks ± 2.3 weeks.
Bone mineral density scores during the inpatient period
revealed all patients to have femoral neck osteoporosis in
the non-fracture site. One-hundred and twenty-seven
patients were discharged as full weight bearing on the
affected hip while remaining patients were at least 75%
weight bearing. All patients were prescribed a gait aid on
discharge. The FFS significantly decreased from admission
(p < 0.001), while walking distance (p < 0.05), FIM (p <
0.01) and BBS (p < 0.001) were all significantly increased
(Additional file 1).
At 6 weeks post discharge all patients returned for fol-
lowup assessment. Only 16 patients regularly used a pre-
scribed gait aid. We observed a significant decrease in
Vitamin D (p < 0.001) and calcium (p < 0.01) compared
to discharge (Additional file 1). All patients remained
compliant with residronate therapy. None of the patients
were using DVT prophylaxis therapy. Fear of falling score,
FIM, and BBS were similar to discharge (p > 0.05) while
walking distance was significantly decreased from dis-
charge (p < 0.05). All patients were seen by their family
physician by 6 weeks followup. All family physicians had
competed pre-study Canadian Consensus detailing and
VAS perceived confidence and knowledge questions. Per-
ceived osteoporosis management confidence was 9.4 ±
0.9 while perceived knowledge of management recom-
mendations was 7.9 ± 1.3.
At twelve months followup, 71 patients remained on
residronate, and 10 were taking alternate bisphosphonate
(Additional file 1). Reasons for discontinuing bisphos-
phonate included a lack of perceived efficacy, non-specific
side-effects, and constitutional symptoms including con-BMC Family Practice 2006, 7:31 http://www.biomedcentral.com/1471-2296/7/31
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stipation. Fear of falling score had significantly decreased
from discharge toward admission score (p < 0.05), while
FIM (100) and BBS (39) had also decreased back to dis-
charge scores but these changes were not statistically sig-
nificant. Walking distance was unchanged from the 6
week distance but significantly reduced from discharge (p
< 0.01). Only eight patients regularly used a gait aid at
twelve months but only two of these were prescribed.
Bone mineral density scores showed no significant change
from discharge among participants who had discontinued
bisphosphonate. Those who remained on a bisphospho-
nate significantly improved their femoral neck BMD score
(p < 0.05) (Additional file 1). Only 20 physicians recalled
the Canadian Consensus recommendations and felt these
materials assisted their osteoporosis management. Sur-
prisingly, perceived confidence and knowledge VAS scores
were unchanged (8.9 and 9.5 respectively) for the group
from discharge (Additional file 1).
Additional file 2 presents the odds ratio (OR) estimates
and 95 % confidence intervals (CIs) for the association of
hip fracture, patient age, number of co-morbidities and
FFS with the use of osteoporosis recommended treatment
at twelve months. Compared with those who were older,
those patients who were < 70 years of age were more likely
to continue osteoporosis treatment at twelve months. Fur-
ther, those patients with a higher FFS and greater number
of co-morbidities tended to continue osteoporosis recom-
mended therapy at twelve months.
Discussion
In a large representative cohort of patients admitted for
rehabilitation following a hip fracture very few previously
had a BMD or received recommended osteoporosis ther-
apy. Admission for rehabilitation was associated with
high scores for fear of falling and previous fall behavior.
While all patients continued recommended bisphospho-
nate therapy at six weeks, most had discontinued calcium
and vitamin D. Further, most had discontinued bisphos-
phonate by 12 months while continued calcium or vita-
min D. This was despite documented osteoporosis and
followup with their family physician who expressed a
high degree of perceived confidence and knowledge
regarding osteoporosis management recommendations.
Patients who were taking osteoporosis therapy or had pre-
vious BMD on admission tended to be younger, have less
fear of falling and were more functionally independent.
Further, being younger, having less fear of falling and
being more functionally independent was associated with
higher likelihood of remaining on recommended therapy
at 12 months post discharge after hip fracture. Conversely,
patients at higher risk for functional dependence in terms
of co-morbidities, fear of falling, previous fall history, and
FIM were less likely to have been on recommended oste-
oporosis therapy or have had a BMD at the time of frac-
ture, and were less likely to continue osteoporosis
recommended therapy at twelve months. Age as a risk fac-
tor for inadequate treatment has been previously docu-
mented for many conditions [14,25], including
osteoporosis.[4,16,20]. Nonetheless, given the fact that
osteoporosis is, itself, an age related condition and that
increasing age is a powerful independent risk factor for
future fracture as well as a second fracture, we might have
expected that elderly patients would be more likely, and
not less likely, to receive treatment than their younger
patients who had lower risk. A 75-year-old woman has, on
average, a life expectancy of twelve years [14] and the ben-
efits of osteoporosis treatment, in terms of increasing
bone marrow density and decreased fracture risk are seen
within a year [16,26]. Certainly, Ensrud et al [10] has sug-
gested that it may never be too late, in life or in the disease
process, to prevent fractures with appropriate treatment.
Overall, our results are concordant with those in previous
studies [4,11,15-20]. The problem of under treatment of
osteoporosis in patients with symptomatic fracture has
been documented using different methods, across differ-
ent populations, and at different health care delivery sys-
tems. Certainly in our cohort there was no problem with
access to treatment and all patients had a family physician
who were not only confident in their ability to treat oste-
oporosis but they also received a brief educational inter-
vention regarding osteoporosis recommendations.
Further, all patients were prescribed osteoporosis therapy
during and following discharge from the MSK rehabilita-
tion program. It is interesting therefore, that under treat-
ment was so prevalent. Although many barriers to optimal
treatment may exist, one of the major contributors to this
problem may be at the level of the health care delivery sys-
tem. This seems to be corroborated by our results. There
seems to be a clinical disconnection between physicians
responsible for treating symptomatic fractures, and the
primary care physicians who are responsible for the detec-
tion and ongoing management of osteoporosis [4,16]. We
believe that any health care system that does not explicitly
provide the means to link acute and primary care provid-
ers will be at risk for delivering sub-optimal osteoporosis
care.
In addition, an element of clinical inertia may be present
as shown in previous studies.[20] Clinical inertia or the
failure of the health care providers to initiate or change
treatment when the health status of a patient indicates
that such a condition is necessary, has been described for
several other chronic medical conditions including diabe-
tes, hypertension, and hyperlipidemia.[17,18,27,28] Fur-
ther, patients may have misconceptions regarding the
importance of ongoing treatment of chronic diseases.[29]
Thus recommended strategies to avoid clinical inertiaBMC Family Practice 2006, 7:31 http://www.biomedcentral.com/1471-2296/7/31
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have included the provision of various forms of educa-
tion; systematic, targeted reminders and feedback from
practice performance; and the development of consensus
guidelines to address important quality of care problems
in these clinical conditions.[18] These implementation
systems should be explored further in primary care set-
tings.
There may have been a view among family physicians that
insufficient evidence existed about the optimal manage-
ment of osteoporotic fractures. However, we provided the
most recent Canadian Consensus recommendations(2)
and a clear statement that was emphasized within these
recommendations regarding appropriate prevention and
therapeutic measures in particular with calcium, Vitamin
D, and bisphosphonates.
The major strength of this prospective study was the lon-
gitudinal design over 12 months and the linked access of
the rehabilitation setting to the attending primary care
physicians. Further, our ability to address the perception
of knowledge regarding osteoporosis treatment and pre-
vention was enhanced through direct survey of the attend-
ing physicians within our patient cohort. We provided not
only the recommendations for osteoporosis prevention
and management but provided discharge prescriptions of
these medications prior to the patients attending to their
family physician. These strategies should have facilitated
management of these patients at 12 months. However, it
is clear that more structured implementation systems and
followup are required. We also collected corroborative
outcome measures related to patient risk of future falls,
fracture and disability. We were surprised to see those
patients at higher rather than lower risk were more likely
not to receive recommended osteoporosis therapy.
Some limitations should also be noted. Inclusion of a
more comprehensive osteoporosis management tool with
recent supportive studies may have maintained higher
rates of osteoporosis management among these patients.
Certainly Consensus Guidelines are only guidelines and
are based on the best available evidence at that time but
some clinicians may prefer to weigh the evidence them-
selves despite knowledge of guidelines as seen in other
therapeutic areas. [30] Conversely, addition of more clin-
ical data may been an overburden and may have further
diluted the minimal educational intervention we used
and produced even poorer results. It would have been
interesting to see what the standard of care among physi-
cians was for other patients with osteoporosis not admit-
ted for fracture. Further, inclusion of a comparator group
(ie. no osteoporosis) or condition (ie. hypertension) may
have provided insight regarding more systemic issues of
chronic disease management in family practice.
Given the heterogeneity of our study population we were
able to include both men and women who had suffered
an osteoporotic fracture however few men were admitted
during the study period. The age diversity also allowed us
to understand some of the present gaps in treatment
related to age. One of our assumptions was that estrogen
therapy was likely prescribed for osteoporosis treatment
as its efficacy in terms of cardiovascular protection was an
issue that was clearly described during the course of our
study. However, it is also plausible that women may have
started their estrogen therapy prior to the disclosure of
this new information and continued on it despite the evi-
dence. Other patients may have been on estrogen therapy
because of menopausal symptoms. However, very few
patients took estrogen treatment at admission and did not
alter this over 12 months such that this aspect of oste-
oporosis therapy was unlikely to have affected our results.
Conclusion
In conclusion, we found that the vast majority of patients
who had suffered an osteoporotic fracture were not taking
recommended therapy at admission or 12 months post
discharge from a rehabilitation program despite prescrip-
tion of recommended osteoporosis therapy at discharge
and the use of an educational intervention for family phy-
sicians. These findings were despite improved BMD at 12
months among those who did adhere to prescribed ther-
apy at discharge and high levels of perceived confidence
and knowledge regarding osteoporosis therapy among
their family physicians. Older age, increased fear of falling
and impaired functional independence and mobility
seemed to be related to lower likelihood of patients being
maintained on osteoporosis treatment at 12 months. Our
findings suggest an opportunity to improve the quality of
osteoporosis care in family practice. It is unlikely that
publication of consensus recommendations or didactic
dissemination of clinical practice guidelines alone are or
will be sufficient to improve osteoporosis management in
patients at high risk for recurrent fractures and morbidity.
Certainly to close this care gap and improve the quality of
care for patients with osteoporotic fractures, we believe
that innovative, multi-faceted interventions need to be
developed and implemented in cooperation with the
health care system, primary care, rehabilitation physicians
and patients.
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